Supporting this work, we previously identified OB-cadherin as frequently expressed in CTCs from patients with metastatic breast and prostate cancer (18), and OB-cadherin mechanistically promotes metastasis to bone in preclinical models of prostate cancer [37]. The gene discussed is CDH11; the disease is prostate cancer.